477 related articles for article (PubMed ID: 26346941)
1. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
[TBL] [Abstract][Full Text] [Related]
2. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
5. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
7. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
Factor SA; Remington G; Comella CL; Correll CU; Burke J; Jimenez R; Liang GS; O'Brien CF
J Clin Psychiatry; 2017; 78(9):1344-1350. PubMed ID: 29141124
[TBL] [Abstract][Full Text] [Related]
9. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
Luo R; Bozigian H; Jimenez R; Loewen G; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):44-52. PubMed ID: 28839339
[TBL] [Abstract][Full Text] [Related]
10. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
[TBL] [Abstract][Full Text] [Related]
11. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
[TBL] [Abstract][Full Text] [Related]
12. Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Jul; 71(7):. PubMed ID: 28497864
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
Fernandez HH; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Meltzer HY; Woods SW; Bega D; LeDoux MS; Shprecher DR; Davis C; Davis MD; Stamler D; Anderson KE
Neurology; 2017 May; 88(21):2003-2010. PubMed ID: 28446646
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
Thai-Cuarto D; O'Brien CF; Jimenez R; Liang GS; Burke J
Drug Saf; 2018 Apr; 41(4):429-440. PubMed ID: 29218680
[TBL] [Abstract][Full Text] [Related]
15. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
16. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
[TBL] [Abstract][Full Text] [Related]
17. The effects of valbenazine on tardive dyskinesia in older and younger patients.
Sajatovic M; Alexopoulos GS; Burke J; Farahmand K; Siegert S
Int J Geriatr Psychiatry; 2020 Jan; 35(1):69-79. PubMed ID: 31617235
[TBL] [Abstract][Full Text] [Related]
18. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M; Pigato G; Kane JM; Correll CU
Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
[TBL] [Abstract][Full Text] [Related]
19. Valbenazine for the treatment of tardive dyskinesia.
Barquero N
Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
Fernandez HH; Stamler D; Davis MD; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Woods SW; Bega D; LeDoux MS; Shprecher DR; Anderson KE
J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1317-1323. PubMed ID: 31296586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
